Synergy Pharmaceuticals (SGYP) Stock Price Up 0%
Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) rose 0% during trading on Tuesday . The stock traded as high as $2.08 and last traded at $2.07. Approximately 3,825,500 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 7,479,984 shares. The stock had previously closed at $2.07.
SGYP has been the subject of several analyst reports. HC Wainwright set a $7.00 target price on shares of Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Monday, December 4th. Cantor Fitzgerald reiterated a “buy” rating and issued a $10.00 target price on shares of Synergy Pharmaceuticals in a report on Thursday, January 25th. BidaskClub downgraded shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, February 6th. Oppenheimer downgraded shares of Synergy Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, January 4th. Finally, Canaccord Genuity set a $13.00 target price on shares of Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 12th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $8.28.
The stock has a market cap of $505.65, a PE ratio of -1.77 and a beta of 1.13. The company has a debt-to-equity ratio of -68.13, a quick ratio of 3.88 and a current ratio of 4.26.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.